Patents by Inventor Patrick J. Stern

Patrick J. Stern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TLR2 modulator compounds, pharmaceutical compositions and uses thereof
    Patent number: 11951094
    Abstract: The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: April 9, 2024
    Assignee: Axial Therapeutics, Inc.
    Inventors: Christopher J. Oalmann, Dennis S. Yamashita, Patrick J. Stern
  • TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20230051773
    Abstract: The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.
    Type: Application
    Filed: June 15, 2022
    Publication date: February 16, 2023
    Applicant: Axial Therapeutics, Inc.
    Inventors: Christopher J. Oalmann, Dennis S. Yamashita, Patrick J. Stern
  • CONDITIONAL PROTEIN TRANSLATION SWITCHES, CONDITIONAL GENE EXPRESSION SYSTEMS AND USES THEREOF
    Publication number: 20200216842
    Abstract: Disclosed herein are protein translation switches and conditional gene expression systems that are compatible with retroviral and lentiviral gene delivery. The linking of a protein translation switch to a 3? gene of interest suppresses translation of the gene of interest, and the alteration of the protein translation switch by DNA recombinase-mediated DNA recombination relieves the suppressed translation of the 3? gene of interest. Also disclosed herein are methods of mimicking clinical pharmacology in a pre-clinical setting.
    Type: Application
    Filed: October 11, 2018
    Publication date: July 9, 2020
    Applicant: Massachusetts Institute of Technology
    Inventor: Patrick J. Stern
  • CONDITIONAL PROTEIN TRANSLATION SWITCHES, CONDITIONAL GENE EXPRESSION SYSTEMS AND USES THEREOF
    Publication number: 20190112600
    Abstract: Disclosed herein are protein translation switches and conditional gene expression systems that are compatible with retroviral and lentiviral gene delivery. The linking of a protein translation switch to a 3? gene of interest suppresses translation of the gene of interest, and the alteration of the protein translation switch by DNA recombinase-mediated DNA recombination relieves the suppressed translation of the 3? gene of interest. Also disclosed herein are methods of mimicking clinical pharmacology in a pre-clinical setting.
    Type: Application
    Filed: October 11, 2018
    Publication date: April 18, 2019
    Applicant: Massachusetts Institute of Technology
    Inventor: Patrick J. Stern